Broader pneumonia protection from birth
Today, countries have an opportunity to broaden protection against pneumonia, the leading infectious killer of children—and make existing vaccine budgets go further.
Pneumococcal conjugate vaccines (PCVs) already protect millions of children against Streptococcus pneumoniae, the leading bacterial cause of childhood pneumonia. New maternal RSV vaccination adds protection against a leading viral cause and a major driver of infant hospitalization. Given during pregnancy, it protects babies through their vulnerable first months.
Complementary vaccines, overlapping benefits
The benefits may work both ways: PCV vaccination has been associated with fewer RSV hospitalizations, while RSV prevention with nirsevimab has been associated with fewer hospitalizations for invasive pneumococcal disease. These findings strengthen the case for tackling bacterial and viral threats together.
However, financing broader protection is currently a challenge, as immunization budgets come under pressure. This is where optimizing PCV programs can help. Countries can release substantial savings by choosing a lower-cost PCV product, such as Pneumosil, where appropriate, and even more by switching from three to two doses of PCV, if they are eligible.











